Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
171.3 EUR | -0.35% | +2.88% | +18.88% |
Jun. 07 | Health Care Up as Defensive Rotation Continues - Health Care Roundup | DJ |
Jun. 06 | Merck KGaA Completes EUR180 Million German Distribution Center Expansion | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With a 2024 P/E ratio at 24.91 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.8 times its current sales, is high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.88% | 81.33B | A | ||
+14.11% | 9.14B | A- | ||
-14.14% | 4.89B | A- | ||
+43.39% | 4.61B | - | ||
+18.90% | 4.36B | B- | ||
+7.93% | 2.26B | B | ||
-28.40% | 2.15B | C- | ||
+15.93% | 2.1B | - | - | |
-43.17% | 1.78B | - | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck KGaA